David Finkelstein

Dr. David I. Finkelstein received a BSc (1979 LaTrobe University, Melbourne Australia), MSc (1986) and PhD in Physiology (1991) from Monash University, Australia. He is a full time researcher that gives specialist undergraduate and postgraduate lectures in neurobiology and anatomy to science, medical and physiotherapy students. His research investigates the neurobiology on neurodegeneration with particular emphasis on the processes that occur during Parkinson’s Disease. He has produced around 100 publications in refereed journals as well as numerous book chapters and international conference presentations. He is a scientific consultant for two biotechnology companies producing and developing novel small molecules for the treatment of neurodegenerative diseases (Parkinson’s, Alzheimer’s and Huntington’s Diseases). He is an editor and a reviewer for many international journals and granting bodies.

1books edited

Latest work with IntechOpen by David Finkelstein

Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.

Go to the book